Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRU-016 plus bendamustine versus bendamustine alone in relapsed chronic lymphocytic leukemia
2010-019554-41Phase 2Completed
- Sponsor
- Trubion Pharmaceuticals
- Start
- Jul 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing TRU-016 + bendamustine with bendamustine alone (2 arms). Primary endpoint: Incidence of dose-limiting toxicities. Started Jul 2010; status: completed.
02
Drugs
Otlertuzumabbendamustine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2010-019554-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019554-41.